title: Furosemide with saline hydration for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: a meta-analysis of randomized controlled trials.
abstract: BACKGROUND
  The clinical efficacy of furosemide administration in preventing contrast-induced nephropathy (CIN) remains uncertain. This meta-analysis was designed to update data on the incidence of CIN with additional furosemide treatment beyond saline hydration in comparison with hydration alone in patients undergoing percutaneous coronary intervention (PCI).
  
  
  METHODS
  A computerized literature search of MEDLINE, EMBASE, and Cochrane databases was performed. Trials were eligible if they enrolled patients undergoing coronary angiography and randomly allocated participants to receive furosemide administration in addition to saline hydration or saline hydration alone. We calculated odds ratios (ORs) and 95% confidence intervals (CIs) for combinations of studies.
  
  
  RESULTS
  Five trials involving 1294 patients (640 for additional furosemide treatment and 654 for hydration alone) were included in the meta-analysis. In the synthesis of data, additional furosemide administration had little impact on the incidence of CIN post-PCI compared with peri-procedural saline hydration alone (OR=0.96; 95% CI 0.33-2.84, p=0.95). Moreover, as for the subsequent need for dialysis, there was no statistical significant difference between the 2 groups (OR=1.01; 95% CI 0.38-2.67, p=0.99). Sensitivity analyses did not show any relevant influence on the overall results. There was no publication bias in the meta-analysis.
  
  
  CONCLUSIONS
  Furosemide administration did not achieve additional benefit beyond saline hydration in reducing the incidence of CIN in patients undergoing PCI.
authors.affiliation: Department of Cardiology, First Affiliated Hospital, Henan University of Science and Technology, Luoyang, Henan, China (mainland).
authors.forename: Nana
authors.initials: N
authors.lastname: Duan
authors.affiliation: Department of Cardiology, First Affiliated Hospital, Henan University of Science and Technology, Louyang, Henan, China (mainland).
authors.forename: Jiegang
authors.initials: J
authors.lastname: Zhao
authors.affiliation: Department of Cardiology, First Affiliated Hospital, Henan University of Science and Technology, Luoyang, Henan, China (mainland).
authors.forename: Zhuanzhen
authors.initials: Z
authors.lastname: Li
authors.affiliation: Department of Cardiology, First Affiliated Hospital, Henan University of Science and Technology, Luoyang, Henan, China (mainland).
authors.forename: Pingshuan
authors.initials: P
authors.lastname: Dong
authors.affiliation: Department of Cardiology, First Affiliated Hospital, Henan University of Science and Technology, Luoyang, Henan, China (mainland).
authors.forename: Shaoxin
authors.initials: S
authors.lastname: Wang
authors.affiliation: Department of Cardiology, First Affiliated Hospital, Henan University of Science and Technology, Luoyang, Henan, China (mainland).
authors.forename: Yuwei
authors.initials: Y
authors.lastname: Zhao
authors.affiliation: Department of Cardiology, First Affiliated Hospital, Henan University of Science and Technology, Luoyang, Henan, China (mainland).
authors.forename: Liping
authors.initials: L
authors.lastname: Wang
authors.affiliation: Department of Cardiology, First Affiliated Hospital, Henan University of Science and Technology, Luoyang, Henan, China (mainland).
authors.forename: Hongyun
authors.initials: H
authors.lastname: Wang
mesh_terms: D000368:Aged; D003287:Contrast Media / Q000009:adverse effects*; D017023:Coronary Angiography / Q000009:adverse effects*; D005260:Female; D005440:Fluid Therapy; D005665:Furosemide / Q000627:therapeutic use*; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced* / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D062645:Percutaneous Coronary Intervention; D016032:Randomized Controlled Trials as Topic; D006435:Renal Dialysis; D012680:Sensitivity and Specificity; D012965:Sodium Chloride / Q000737:chemistry*; D049994:Sodium Potassium Chloride Symporter Inhibitors / Q000627:therapeutic use
chemical_list: D003287:Contrast Media; D049994:Sodium Potassium Chloride Symporter Inhibitors; D012965:Sodium Chloride; D005665:Furosemide